BELLUS Health Inc. (BLU)

10.650
+0.040(+0.38%)
  • Volume:
    3,019
  • Bid/Ask:
    10.620/10.660
  • Day's Range:
    10.480 - 11.240

BLU Overview

Prev. Close
10.61
Day's Range
10.48-11.24
Revenue
-
Open
10.48
52 wk Range
7.43-16.2
EPS
-1.08
Volume
3,019
Market Cap
1.35B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
4,421
P/E Ratio
-12.04
Beta
-0.56
1-Year Change
29.39%
Shares Outstanding
126,567,121
Next Earnings Date
09 May 2023
What is your sentiment on BELLUS Health Inc.?
or
Market is currently closed. Voting is open during market hours.

BELLUS Health Inc. Company Profile

BELLUS Health Inc. Company Profile

  • Type:Equity
  • Market:Canada
  • ISIN:CA07987C2040
  • CUSIP:07987C204

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyBuyBuy
Technical IndicatorsStrong SellSellBuyStrong BuySell
SummaryStrong SellNeutralBuyStrong BuyNeutral